Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential versus alternating MPV and Rd in newly diagnosed multiple myeloma patients older than 65 years
2010-018379-70Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- May 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, lenalidomide, melphalan, prednisone and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Progression-free survival at 18 months. Started May 2010; status: active.
02
Drugs
bortezomiblenalidomidemelphalanprednisonedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-018379-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018379-70.